Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-22 02:01 UTC

BIOMED PULSE

Tuesday, September 22, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the DRC, with sustained cross-border transmission into Uganda ongoing. The overall mood is ELEVATED CONCERN: multiple simultaneous outbreaks — Ebola, drug-resistant bacteria, and food safety crises — are stretching public health systems with no clear resolution in sight.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA — DRC AND UGANDA (ACTIVE, EXPANDING)

  • As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak spans 61 health zones across six DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, with ongoing cross-border transmission to Uganda. [1]
  • The outbreak is formally the largest Ebola event ever documented in DRC history, growing faster than any previous Ebola outbreak on record according to WHO. [2]
  • The most recent WHO Disease Outbreak News, dated September 10, 2026 (DON617), notes the addition of one new health zone — Kayna in North Kivu — since the previous update of August 28, 2026. [1]
  • As of the August 28 DON616 update, six additional health zones had newly reported cases since the August 14 DON615, bringing the prior total to 60 affected zones. [3]
  • WHO first confirmed the outbreak origin in Mongbwalu Health Zone, Ituri Province, following an alert of high-mortality unknown illness on May 5, 2026, with Bundibugyo virus (a filovirus distinct from Zaire ebolavirus) confirmed by the Institut national de recherche biomédicale on May 14, 2026. [4]
  • Cumulative confirmed cases stood at 2,124 with 828 deaths as of July 15, 2026 (DON613); the case count has continued rising through August and September updates. [5]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and expanded airport entry screening first to Washington-Dulles International Airport (May 21, 2026) and subsequently to Atlanta. [6] [7] [8]

DRUG-RESISTANT BACTERIA — USA (NEW REPORT)

  • A CDC report released September 23, 2026, found a dramatic increase in dangerous drug-resistant bacteria, described as a sharp rise requiring urgent action. [9]
  • This follows a prior CDC antimicrobial resistance threat pattern that has concerned public health officials across multiple years. [9]

ANIMAL RABIES — USA (EMERGING SIGNAL)

  • CDC issued a statement on September 10, 2026, warning of increases in recent animal rabies activity and associated human exposures across the United States. [10]

MEASLES — BANGLADESH (ONGOING, WHO-NOTIFIED)

  • On April 23, 2026, WHO reported a nationwide measles surge in Bangladesh affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases as of the notification date.

CONGENITAL SYPHILIS — USA (NEW CDC DATA)

  • New CDC data released September 24, 2026, show U.S. newborn syphilis cases increased for the 12th consecutive year in 2024, continuing a deeply troubling multi-year trend.

FOODBORNE OUTBREAKS — MULTIPLE ACTIVE (USA)

  • CDC expanded a Listeria outbreak alert on September 26, 2026, to include additional prepared foods, reporting 3 new illnesses and 1 additional death since the previous update.
  • A Salmonella outbreak linked to Metabolic Meals home delivery foods was active as of September 5, 2026, with 16 people ill across 10 states.
  • An earlier egg-linked Salmonella outbreak had sickened 95 people across 14 states as of August 28, 2026.

🧬 LONGEVITY & AGING

SENESCENCE IN HAIR FOLLICLES — IONIZING RADIATION MECHANISM

  • A study published in Genes and Disease (Jia Z et al.) found that ionizing radiation drives senescence of dermal papilla cells — the stem-cell-like cells that control hair follicle cycling — by suppressing the FOXM1-KIF20A signaling pathway, a finding relevant to radiation-associated hair loss and skin aging.

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE — MEASUREMENT TOOLS

  • Koutsoukos SA et al. published a methodology paper in Methods in Molecular Biology describing multiplex assay approaches to characterize the senescence-associated secretory phenotype (SASP) in both primary skin cells and induced pluripotent stem cell-derived skin cells, advancing standardized senescence measurement.

BONE AGING — mRNA LIPID NANOPARTICLE THERAPY

  • Cheng M et al. (Bioactive Materials, August 2026) demonstrated that a dual-targeting mRNA lipid nanoparticle restoring ABCA1-dependent cholesterol homeostasis can promote repair of age-related bone defects in preclinical models, linking lipid metabolism in aged bone tissue to regenerative capacity.

BONE AGING — OSTEO-ORGANOID APPROACH

  • Zhu F et al. (Bioactive Materials, August 2026) showed that BMP-2-driven osteo-organoids retain key osteogenic-support features and can promote bone repair even after total-body irradiation, suggesting organoid therapy as a strategy for radiation- or age-damaged skeletal tissue.

OSTEOPOROSIS — NANOCOMPOSITE HYDROGEL REGENERATION

  • Yin H et al. (Bioactive Materials, August 2026) developed a quercetin-derived carbon dot-modified ZIF-8 and M2 macrophage-derived migrasome-functionalized nanocomposite hydrogel that responds to the microenvironment of osteoporotic bone defects, aiming to regenerate aged or fragile bone tissue.

OSTEOARTHRITIS — EXTRACELLULAR VESICLE BIOLOGY

  • Yang Z et al. (Bioactive Materials, September 2026) reviewed how extracellular vesicles function in a context-dependent manner in osteoarthritis — acting as either pathogenic drivers or reparative agents — pointing toward vesicle engineering as a target for age-related joint disease treatment.

INTERVERTEBRAL DISC AGING — BIOMATERIALS REVIEW

  • Jiang Y et al. (Bioactive Materials, September 2026) published a comprehensive review on biomaterial strategies for intervertebral disc regeneration, covering niche reprogramming, precision therapeutics, and structural reconstruction approaches relevant to spinal aging.

FRAILTY AND INFLUENZA VACCINE DOSE — DANFLU-2 TRIAL ANALYSIS

  • Espersen C et al. (Lancet Healthy Longevity) conducted a prespecified analysis of the randomized DANFLU-2 trial finding that high-dose influenza vaccine was more effective than standard-dose in preventing hospitalization specifically among frail older adults, even though frailty itself confers elevated baseline risk of severe influenza.
  • An accompanying commentary by Verschoor CP and Kuchel GA labeled this the frailty-influenza paradox — frail individuals face the greatest danger from influenza yet derive the greatest benefit from dose-intensified vaccination.

ANAESTHESIA CHOICE AND HIP FRACTURE OUTCOMES IN OLDER PATIENTS

  • A multicentre randomized clinical trial from Germany (Kowark A et al., Lancet Healthy Longevity) compared spinal versus general anaesthesia for hip fracture surgery in older patients, directly testing whether anaesthetic mode affects serious postoperative complications in a geriatric surgical population.
  • An editorial by Moppett I and Shelton C framed the results as potentially closing a long-debated question in geriatric perioperative medicine.

ATHEROSCLEROSIS — NARCICLASINE AS DUAL VCAM-1/ICAM-1 INHIBITOR

  • Wang Y et al. (Genes and Disease) used single-cell sequencing to identify narciclasine as a dual inhibitor of VCAM-1 and ICAM-1 — two adhesion molecules central to vascular inflammation and atherosclerotic plaque formation — positioning this natural compound as a candidate for age-related cardiovascular disease management.

DEPRESCRIBING IN OLDER ADULTS — TRIAL DESIGN DEBATE

  • Hwang CS, Boockvar KS, and Steinman MA (Lancet Healthy Longevity) argued that deprescribing clinical trials must adopt a rationale-first framework — establishing the biological and clinical justification before selecting trial design — to avoid testing medication withdrawal in inappropriate patient subgroups.
  • A separate response by Van der Linden LR offered a complementary perspective on this framework, underscoring the growing research momentum around safely reducing polypharmacy in aging populations.

MOLECULAR HYDROGEN — RADIATION PROTECTION POTENTIAL

  • Ichikawa Y et al. (Medical Gas Research, September 2026) reviewed evidence that molecular hydrogen may act as a guardian against environmental radiation damage, relevant to both longevity (oxidative stress reduction) and radiation exposure contexts.

💊 NEW CURES & APPROVALS

No new openFDA drug approvals appeared in today's official data feed. The trial item most proximal to an approval-stage intervention is deucrictibant (see Clinical Trials section below).

🧪 CLINICAL TRIALS

DEUCRICTIBANT XR — PHASE 3 ANGIOEDEMA PROPHYLAXIS (NCT07266805, REGISTERED SEPTEMBER 21, 2026)

  • A Phase 3, multicenter, three-part study — including two randomized double-blind placebo-controlled parts and an open-label extension — is evaluating oral deucrictibant XR tablet for prophylaxis and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adults with acquired C1 inhibitor deficiency, a rare and potentially life-threatening swelling disorder.

ALZHEIMER'S DISEASE — TRANSCRANIAL STIMULATION IN OLDER ADULTS (NCT04018092, UPDATED SEPTEMBER 21, 2026)

  • The Revitalize Study is a multi-site, double-blinded, randomized sham-controlled Phase II trial testing transcranial magnetic stimulation as a low-cost, low-risk intervention in older adults at increased risk for Alzheimer's disease, with the primary goal of assessing efficacy of the novel neurostimulation approach.

ATRASENTAN — PEDIATRIC IgA NEPHROPATHY (NCT07498335, REGISTERED SEPTEMBER 21, 2026)

  • A Phase III single-arm multicenter study is evaluating atrasentan — an endothelin receptor antagonist already studied in adults — in children and adolescents aged 2 to under 18 years with primary immunoglobulin A nephropathy (IgAN), a kidney disease with aging-relevant fibrosis mechanisms.

FREXALIMAB — KIDNEY TRANSPLANTATION IMMUNOSUPPRESSION (NCT07412470, UPDATED SEPTEMBER 21, 2026)

  • An open-label, randomized, active-comparator-controlled study is comparing frexalimab subcutaneous injections (a CD40L-targeting antibody) versus tacrolimus capsules over up to 5 years in adults aged 18 to 70 undergoing kidney transplantation, with the goal of reducing calcineurin-inhibitor toxicity in an aging transplant population.

NEMTABRUTINIB — CLL/SLL REFRACTORY TO BTK AND BCL2 INHIBITORS (NCT07796373, REGISTERED SEPTEMBER 21, 2026)

  • A study is testing nemtabrutinib — a non-covalent Bruton tyrosine kinase inhibitor — in patients with chronic lymphocytic leukemia or small lymphocytic leukemia that is refractory to covalent BTK inhibitors or pirtobrutinib and previously treated with a BCL2 inhibitor, addressing a population with severely limited options.

MIRDAMETINIB PLUS SIROLIMUS — RAS-MUTATED MULTIPLE MYELOMA (NCT06876142, UPDATED SEPTEMBER 21, 2026)

  • A combination therapy trial is studying MEK inhibitor mirdametinib with mTOR inhibitor sirolimus in relapsed/refractory multiple myeloma bearing KRAS or NRAS mutations, targeting a pathway dysregulation common in older myeloma patients.

RECOMBINANT MALARIA VACCINES LYB014, LYB017, LYB027 — PHASE 1/2 (NCT07831226, REGISTERED SEPTEMBER 21, 2026)

  • Healthy volunteers aged 18 to 59 are being enrolled to receive one of three investigational malaria vaccines (LYB014, LYB017, LYB027) combined with A02B adjuvant, or A02B adjuvant alone as control, in a safety and immunogenicity study.

📢 PUBLIC HEALTH

CDC DRUG-RESISTANT BACTERIA ALERT (SEPTEMBER 23, 2026)

  • CDC's new report documenting a sharp rise in dangerous drug-resistant bacteria reinforces the urgency of antibiotic stewardship in all healthcare settings across the United States. [9]

CDC LISTERIA OUTBREAK — PREPARED MEALS (ONGOING)

  • CDC urges consumers to check refrigerators and freezers immediately for recalled prepared meal products linked to the active Listeria monocytogenes outbreak; new deaths have been reported as recently as September 26, 2026.

CONGENITAL SYPHILIS — 12TH CONSECUTIVE ANNUAL INCREASE

  • CDC's September 24, 2026, data release confirms newborn syphilis continues its unbroken annual rise through 2024, calling for expanded prenatal screening and STI treatment access.

ANIMAL RABIES EXPOSURES — USA INCREASE

  • CDC flagged elevated animal rabies activity and higher rates of associated human exposures as of September 10, 2026, advising clinicians and the public to report any animal bites promptly for post-exposure prophylaxis evaluation. [10]

BIOMED PULSE is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
  10. CDC Statement on Increases in Recent Animal Rabies Activity an… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260922-02-v83 · 2026-09-22 02:01 UTC · pulse.uzylab.com

Read next